← Back to Clinical Trials
Recruiting NCT06945549

NCT06945549 Evaluation of Intestinal Lesions and Disease Activity in Inflammatory Bowel Disease Based on 18F-FAPI PET Imaging

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06945549
Status Recruiting
Phase
Sponsor Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Condition Inflammatory Bowel Disease (IBD)
Study Type OBSERVATIONAL
Enrollment 30 participants
Start Date 2025-04-25
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
18F-FAPI PET Imaging

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 30 participants in total. It began in 2025-04-25 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to evaluate the role and effect of 18F-FAPI PET imaging in the identification of intestinal lesions and the assessment of disease activity in inflammatory bowel disease. The main question it aims to answer is: Can 18F-FAPI PET imaging effectively identify intestinal lesions in inflammatory bowel disease and accurately assess disease activity? Colonoscopy, enhanced abdominal CT, and 18F-FAPI intestinal imaging were completed within 1 week, and major adverse outcomes (MAO) were followed up 12 months after enrollment. Last updated on March 25, 2025

Eligibility Criteria

Inclusion Criteria: * Patients diagnosed with IBD according to clinical, imaging, endoscopic, and histopathological criteria; * Patients ≥18 years old; * 18F-FAPI PET/CT intestinal imaging, conventional endoscopic and enhanced CT were performed within 1 week; * Intestinal segment matching was evaluated by endoscopy and imaging; * Patients voluntarily participate and sign informed consent. Exclusion Criteria: * Pregnant or lactating patients; * Imaging images are of poor quality and cannot be used for diagnosis and evaluation; * Patients with contraindications for endoscopic or CT examination.

Contact & Investigator

Central Contact

Wenbo Li, postgraduate

✉ lwb@tmmu.edu.cn

📞 +8615292886778

Frequently Asked Questions

Who can join the NCT06945549 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Inflammatory Bowel Disease (IBD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06945549 currently recruiting?

Yes, NCT06945549 is actively recruiting participants. Contact the research team at lwb@tmmu.edu.cn for enrollment information.

Where is the NCT06945549 trial being conducted?

This trial is being conducted at Chongqing, China.

Who is sponsoring the NCT06945549 clinical trial?

NCT06945549 is sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology